PBM Stock: Psyence Biomedical Ltd. Stock Price, Analysis & Insights
Get live pbm stock price $1.72, comprehensive Psyence Biomedical Ltd. stock analysis, charts, news, and expert forecast. Real-time pbm stock data and investment insights.
Loading chart...
Company Overview
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Company Information
- CEO
- Jody Aufrichtig
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
Contact Information
- Address
- 121 Richmond Street West
- Country
- CA
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 0.0)
✓ Lower volatility stock (Beta: 0.25) may provide portfolio stability
Business Model & Strategy
Psyence Biomedical Ltd. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Jody Aufrichtig, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Psyence Biomedical Ltd. competes in the Biotechnology within the broader Healthcare. With 1.2 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Psyence Biomedical Ltd. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Psyence Biomedical Ltd. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Psyence Biomedical Ltd. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Psyence Biomedical Ltd.
- ⚠Investors should consider how Psyence Biomedical Ltd. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.23M
P/E Ratio
0.04
Beta
0.25
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.23M market capitalization
- Trading Volume: 20.21M shares traded today
- Price Range: 52-week range of $1.58 - $62.96
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Psyence Biomedical Ltd.
Psyence Biomedical Ltd. (PBM) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 1.23M, the company represents a significant player in its market. The stock is currently trading at $1.72 with a negativedaily change of 38.35%.
The company's 10 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 0.04, beta of 0.25, and 52-week price range from $1.58 to $62.96when evaluating investment opportunities.
Why Invest in Psyence Biomedical Ltd.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Jody Aufrichtig
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.